Maze Therapeutics (MAZE) Tax Provisions (2024)

Maze Therapeutics' (MAZE) quarterly Tax Provisions came in at -$200000.0 in Q4 2024, up 33.33% quarter-over-quarter from -$300000.0 in Q3 2024.

Maze Therapeutics (MAZE) Tax Provisions (2024) Analysis & Trends

Maze Therapeutics has disclosed Tax Provisions across 1 years of filings, most recently posting -$200000.0 for Q4 2024.

Tax Provisions for Q4 2024 came in at -$200000.0, changed N/A year-over-year; the trailing twelve-month figure through Dec 2025 was -$200000.0 (changed N/A YoY), and the FY2024 annual result was $1.2 million, changed N/A from the prior year.
Tax Provisions came in at -$200000.0 for Q4 2024 at Maze Therapeutics, up from -$300000.0 in the prior quarter.
In the past five years, Tax Provisions ranged from a high of $1.7 million in Q2 2024 to a low of -$300000.0 in Q3 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Taxes (Qtr)
1	Alterity Therapeutics	814,307.08 Bn	814,307.05 Bn	-	-
2	Belite Bio	55,320.00 Bn	55,320.00 Bn	-	-
3	Quantum Biopharma	17,149.72 Bn	17,149.72 Bn	-	-
4	Legend Biotech	3,590.00 Bn	3,589.71 Bn	242.10 Mn	-11.20 Mn
5	Akari Therapeutics	1,650.72 Bn	1,650.72 Bn	-	-859,000.00
6	Evaxion A	1,522.09 Bn	1,522.07 Bn	-	216,000.00
7	Psyence Biomedical	229.39 Bn	229.38 Bn	-	-
8	Vertex Pharmaceuticals	113.09 Bn	105.85 Bn	2.59 Bn	221.50 Mn
9	Abivax	90.15 Bn	90.15 Bn	-	-
10	Maze Therapeutics	1.31 Bn	1.31 Bn	18.21 Mn	-

Download Data